| bibliographicCitation |
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang C, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Narendran G, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID, Adilaa O, Alexandru S, Bellenger K, Bennet J, Bennet D, Bindroo P, Borisagar G, Cook C, Dalai D, Davis A, de Jong B, Dodds W, Duckworth L, Gahima N, Gebreegziabher B, Goldfeld A, Hanifa M, Hughes G, Kimuli I, Komrska J, Lomtadze N, Murphy B, Mwelase T, Nalunjogi J, Patel L, Pirlog I, Qawiy I, Rauchenberger M, Rigouts L, Roach C, Rosu L, Santos-Filho E, Senguttuvan T, Sisay M, Sridhar R, Srinivasulu V, Teferi M, Teklu H, Tsegeen N, van Amsterdam O, White L, Whitney J, Zagd C. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. The Lancet. 2022 Nov;400(10366):1858–68. doi: 10.1016/s0140-6736(22)02078-5. |